We don't advise from the sidelines. We build companies from scientific and outlier talent — from first diagnosis of an opportunity through to fundraising.
AI is moving from models to execution. The founders best positioned to build in this decade are rarely full-time operators from day one — they're scientists, clinicians, and researchers with an insight no generalist team could arrive at alone. CAI's job is to turn that insight into a company.
A four-stage pipeline that carries a scientific insight from first conversation to a funded company — spanning Toronto's hospital and research network to BioBAY Suzhou.
Sourced from research labs, hospital networks, and clinical practice — not from the standard pitch-deck pipeline.
A structured intake and scoring process, entered through a Diagnostic Sprint that stress-tests the scientific and commercial thesis before any commitment is made.
A Fractional Science Advisory Layer supports the founding team on regulatory strategy, clinical pathway, and go-to-market — without requiring a full executive hire on day one.
Introductions to investors across North America and Asia, sequenced to match the company's regulatory and clinical milestones.
Applied-AI ventures — AI agents, enterprise AI, and AI infrastructure — sit in their own vertical. The diligence bar for a clinical product and a software product isn't the same, so we don't run them through the same process.
"The best way to predict the future is to create it."— Peter Drucker
Founders and research teams — start with a Diagnostic Sprint.